We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Serimmune Launches COVID Antibody Epitope Mapping Service
Product News

Serimmune Launches COVID Antibody Epitope Mapping Service

Serimmune Launches COVID Antibody Epitope Mapping Service
Product News

Serimmune Launches COVID Antibody Epitope Mapping Service

Credit: Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Serimmune Launches COVID Antibody Epitope Mapping Service"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Serimmune Inc., a leader in understanding the functional antibody repertoire’s role in human disease, has announced the launch of a COVID antibody epitope mapping discovery service.  This offering now provides academic and biopharma researchers with ready access to Serimmune’s proprietary Serum Epitope Repertoire Analysis (SERA) technology.

Requiring only 100 ul of serum or plasma per sample, Serimmune analyzes each sample for IgG and/or IgM antibodies using its proprietary, 10 billion member, random, bacterial peptide display library.  In addition to providing a composite score of the antibody epitopes identified in each sample to those observed in cohorts of individuals with mild, moderate and severe COVID-19 disease, the service provides single amino acid resolution epitope data across the entire SARS-CoV-2 proteome for each sample and shows how it compares to a large cohort of pre-pandemic controls and SARS-COV-2 positive samples; all in an easy-to-interpret, interactive html format.

"We have collaborated with Serimmune throughout the pandemic to characterize the humoral response to SARS-CoV-2.”, said Dr. Akiko Iwasaki, Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale School of Medicine. "Due to the flexibility of the SERA platform, we rapidly predicted that the B.1.1.7 variant is unlikely to escape antibodies generated against linear epitopes in prior SARS-CoV-2 infections. This is the tip of the iceberg for what Serimmune can do. I am excited to continue to collaborate with the team.”

“We have seen increasing interest from our academic and biopharma collaborators in utilizing the SERA platform to better understand antibody epitope profiles from naturally infected individuals and those receiving the latest SARS-CoV-2 vaccines,” said Noah Nasser, CEO of Serimmune. “We believe that the launch of this service will provide researchers with broader access to novel scientific insights for the prevention and treatment of COVID-19.”

Learn more about Serimmune’s COVID Epitope Mapping Discovery Service at https://serimmune.com/services/.


Advertisement